Today: 8 June 2026
Browse Category

NASDAQ:WVE 8 December 2025 - 3 February 2026

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares edged up 0.1% to 1,926.5 pence Tuesday, nearing a one-year high ahead of its earnings report due Wednesday. The company is cutting about 350 R&D jobs in the UK and U.S. and recently returned rights to the WVE-006 drug candidate to Wave Life Sciences. Investors await CEO Luke Miels’ first major update and signals on cost controls and R&D priorities.
3 February 2026
····
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences shares fell 6.7% to $13.84 Friday, underperforming biotech peers ahead of the J.P. Morgan Healthcare Conference. Investors are watching for CEO Paul Bolno’s Tuesday update on WVE-007, its obesity drug, after December’s interim data showed a 9.4% visceral fat reduction. The company recently raised $350 million in a public offering.
11 January 2026
··
Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Wave Life Sciences shares dropped 5.6% to $14.00 on Friday, underperforming biotech ETFs. The decline follows a $350 million stock offering and comes ahead of new obesity drug trial data expected later in 2026. Investors remain focused on dilution risks and upcoming updates from management. CEO Paul Bolno will present at the J.P. Morgan Healthcare Conference on January 13.
9 January 2026
·
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences shares surged 17.2% to $17.58 Tuesday on heavy volume, after new data from Arrowhead Pharmaceuticals showed weight loss benefits from RNAi obesity drugs. Wave is developing a similar therapy, WVE-007, targeting the same gene. The company recently raised $402.5 million in a public offering. Investors await further trial results expected in early 2026.
6 January 2026
··
Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences shares fell 6.2% to $15.95 Friday, underperforming the flat Nasdaq Biotechnology Index. The company expects more Phase 1 obesity trial data in Q1 2026. A December SEC filing said Wave’s equity raise, including over-allotments, was expected to bring in about $402.5 million. Early data showed WVE-007 reduced visceral fat by 9.4% at three months in a 32-person cohort.
4 January 2026
·
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences shares fell 0.74% to $18.12 late Thursday morning, underperforming the broader market as biotech stocks slipped. Earlier this month, Wave reported positive Phase 1 data for its obesity drug candidate WVE-007 and raised $402.5 million in an upsized equity offering, extending its cash runway into Q3 2028.
26 December 2025
··
Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next

Wave Life Sciences shares traded around $18.1–$18.5 on December 24, 2025, holding gains after positive WVE-007 obesity data and a recent capital raise. No new company news crossed the wire, but analysts raised fair value targets following the Phase 1 results showing reduced visceral fat and increased lean mass. At least one after-hours trade printed below the regular close amid thin holiday volume.
24 December 2025
··
Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences shares fell to the mid-$15 range on December 18, 2025, following a volatile period sparked by positive Phase 1 data for its obesity drug candidate WVE-007 and a large equity offering. No new announcements drove the move; trading reflected continued volatility after the early December clinical data and financing. Analysts remain bullish, but dilution and early-stage risk weigh on the stock.
18 December 2025
Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

Wave Life Sciences shares rose 5.2% to $16.94 Tuesday after Oppenheimer raised its price target to $32, citing positive interim Phase 1 data for obesity drug WVE-007. The company reported a 9.4% reduction in visceral fat and a 3.2% increase in lean mass at three months after a single dose. Placebo participants saw no significant changes. Wave’s trial enrolled over 100 adults with BMI 28–35.
16 December 2025
··
US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

The Dow Jones closed at a record high Thursday, rising about 1.3–1.4%, while the Nasdaq fell 0.3–0.4% as Oracle shares plunged up to 15% after weak earnings and a surprise AI spending warning. Micro-cap stocks saw steep losses, with Oriental Culture Holding dropping nearly 90%. The S&P 500 edged higher by 0.1–0.2%.
11 December 2025
····
Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences shares surged over 180% in a week after Phase 1 data showed its obesity drug WVE-007 reduced visceral fat by up to 10% and increased lean mass. The stock hit a five-year high near $22 before retreating to $17.06 following a $350 million equity offering and insider selling. Analyst price targets jumped, but Wave remains unprofitable with high valuation risk.
11 December 2025
···
Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More

Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More

Wave Life Sciences shares jumped about 147% Monday after positive data on its experimental RNA obesity drug, leading US stock gainers. The Dow fell 0.45%, S&P 500 lost 0.35%, and Nasdaq slipped 0.14% as investors awaited Wednesday’s Federal Reserve decision. Nvidia rose after the US allowed exports of its H200 AI chips to China with a 25% fee.
9 December 2025
····
Most Active Stocks Today (December 9, 2025): Nvidia, Tesla, Wave Life Sciences and Confluent Lead a Fed-Focused Wall Street

Most Active Stocks Today (December 9, 2025): Nvidia, Tesla, Wave Life Sciences and Confluent Lead a Fed-Focused Wall Street

Nvidia and AI chip stocks led US trading volumes Monday after the Biden administration cleared Nvidia’s H200 chips for export to China, with the government taking a 25% revenue cut. The S&P 500, Dow, and Nasdaq all closed just below record highs. Investors await the Fed’s final 2025 policy decision, with markets expecting a third rate cut this year. Treasury yields and the dollar held steady.
9 December 2025
····
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences shares surged 147% to $18.52 after reporting positive Phase 1 data for its RNA obesity drug WVE-007 on December 8, raising its market cap to $3 billion. The company launched a $250 million equity offering following the rally. Interim results showed a 9.4% reduction in visceral fat and a 3.2% gain in lean mass after one dose, outperforming GLP-1 drugs in early comparisons.
9 December 2025
···
Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences (WVE) Soars 147% on Obesity Drug Breakthrough and $250M Offering: What to Know Before the December 9 Open

Wave Life Sciences shares surged 147% to $18.52 Monday after reporting positive Phase 1 obesity drug data for WVE‑007 and announcing a $250 million equity offering. The stock hit a new 52-week high on record volume, then climbed further to $19.90 in after-hours trading. Interim trial results showed significant fat reduction and increased lean mass after one dose. Analyst ratings remain bullish despite the company’s ongoing losses.
9 December 2025
··
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences shares soared as much as 140% Monday after reporting positive interim Phase 1 data for its obesity drug WVE-007. The stock hit $17–18 intraday on record volume topping 100 million shares, up from Friday’s $7.49 close. The trial showed a 9.4% drop in visceral fat and a 3.2% gain in lean mass at three months. Wave’s market value rose to about $2.5–3.0 billion.
8 December 2025
·
1 2

Stock Market Today

  • Asian Shares Fall as Big Tech Rally Ends and Wall Street Faces Steep Losses
    June 8, 2026, 9:23 AM EDT. Asian stocks declined Monday following a sharp sell-off in Big Tech shares on Wall Street, marking its worst day in months. The drop was fueled by increasing concerns over a potential interest rate hike by the U.S. Federal Reserve, which investors fear may dampen growth prospects for high-valuation technology companies. The tech sell-off weighed on major indexes in Asia, reflecting global investor caution amid tightening monetary policy expectations. This market reaction underscores ongoing volatility tied to central bank decisions and sector-specific risks in technology stock investments.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop